Craig M. Zaidman

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial

John Day, Richard S. Finkel, Claudia A. Chiriboga et al. · The Lancet Neurology · 2021 · 449 citations

Rare Diseases, Spinal Cord Injury, Medicine +5

Peripheral nerve size in normals and patients with polyneuropathy: An ultrasound study

Craig M. Zaidman, Mohammed Al‐Lozi, Alan Pestronk · Muscle & Nerve · 2009 · 339 citations

Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial

Kevin A. Strauss, Michelle A. Farrar, Francesco Muntoni et al. · Nature Medicine · 2022 · 273 citations · Full text

<i>TREM2</i>Variant p.R47H as a Risk Factor for Sporadic Amyotrophic Lateral Sclerosis

Janet Cady, Erica Koval, Bruno A. Benítez et al. · JAMA Neurology · 2014 · 258 citations · Full text

Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial

Kevin A. Strauss, Michelle A. Farrar, Francesco Muntoni et al. · Nature Medicine · 2022 · 255 citations · Full text

Translational Medicine, Spinal Cord Injury, Motor Development +14